B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

ABSTRACT:

Background

Chimeric antigen receptor (CAR) T cells are a promising therapy for hematologic malignancies. B-cell maturation antigen (BCMA) is a rational target in multiple myeloma (MM).

Methods

We conducted a phase I study of autologous T cells lentivirally-transduced with a fully-human, BCMA-specific CAR containing CD3ζ and 4-1BB signaling domains (CART-BCMA), in subjects with relapsed/refractory MM. Twenty-five subjects were treated in 3 cohorts: 1) 1-5 x 108 CART-BCMA cells alone; 2) Cyclophosphamide (Cy) 1.5 g/m2 + 1-5 x 107 CART-BCMA cells; and 3) Cy 1.5 g/m2 + 1-5 x 108 CART-BCMA cells. No pre-specified BCMA expression level was required.

Results

CART-BCMA cells were manufactured and expanded in all subjects. Toxicities included cytokine release syndrome and neur

SUBMITTER: Cohen AD 

PROVIDER: S-EPMC6546468 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature